Management of hemophilia in France.
Two important factors concerning the management of hemophilia in France are considered. The supply of factors VIII and IX for replacement therapy meets the current demand but as the demand increases with the development of self-infusion programs, the production will also have to increase. This can only be done through more effective use of all of the blood components and will require careful evaluation of the needs of each patient. Programs which teach self-infusion and the other aspects of home care are gradually allowing the hemophiliac and his family better understanding of the disease. These programs are developing slowly in France but must be expanded to improve the general care of all French hemophiliacs.
D000553:Ambulatory Care; D005164:Factor IX / Q000627:therapeutic use; D005169:Factor VIII / Q000627:therapeutic use; D005602:France; D006266:Health Education; D006467:Hemophilia A / Q000453:epidemiology / Q000628:therapy*; D006699:Home Care Services; D006801:Humans; D008297:Male; D012651:Self Medication
D005169:Factor VIII; D005164:Factor IX